Generated from the Type1Cure syndication feed — official and public source pulls normalized into evidence-labeled items before they hit the page.
29 items from 3 live sources. Updated Jun 24, 2026, 10:17 PM GMT-5. Sources with temporary failures stay visible in feed health instead of silently disappearing.
RECRUITING, PHASE3. Interventions: Baricitinib, Placebo. Locations: Tallahassee, Florida, United States | Tampa, Florida, United States | Iowa City, Iowa, United States. The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
RECRUITING, NA. Interventions: Bionic Pancreas, Routine Care. Locations: Aurora, Colorado, United States | Boston, Massachusetts, United States. The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main question it aims to answer is: Can t...
RECRUITING, EARLY_PHASE1. Interventions: Dichloroacetate. Locations: New Haven, Connecticut, United States. This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.
RECRUITING, NA. Interventions: Sleep Health and Circadian Timing Intervention. Locations: Aurora, Colorado, United States. Research has shown a link between poor sleep health and late circadian timing with cardiometabolic health in adolescents with type 1 diabetes (T1D). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in T1D, which begins as early as adolescence, and current therapies are limited. Therefore, this study plans t...
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
Kits contain the McKesson TRUE Metrix PRO Professional Monitoring Blood Glucose System that has been recalled for an issue with the software design of the E-5 Error Code where the meter displays an E-5 error code for a very high blood glucose event (> 600 mg/dL) or when there is a test strip error, which can lead to operator confusion when evaluating patients and a delay in ap... Action: On 3/27/2026, correction notices were emailed to customers asking them to take the following actions: For Health Care Profession...
Due to a manufacturing defect, certain Omnipod 5 Pods from 49 lots have an internal soft cannula tear that results in insulin leaking into the Pod instead of being delivered to the user regardless of basal or bolus delivery. This defect results from damage to the unexposed portion of the soft cannula during manufacturing, which would result in a compromised fluid path. The pri... Action: Insulet notified consignees via press release and letters sent via email primarily and also text message on 03/12/2026. The pres...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
A focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
A plain-English watchlist of current recruiting Type 1 diabetes studies surfaced from ClinicalTrials.gov, with consent-first guardrails for families.
A daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Clinical trials, biotech filings, peer-reviewed papers
The highest-value watchlist combines islet or stem-cell derived beta cells, encapsulation, immune modulation, and durable insulin independence endpoints.
FDA, device makers, ADA technology updates
Closed-loop systems, CGM accuracy, interoperability, algorithm updates, infusion-set reliability, and recall notices deserve daily monitoring.
ClinicalTrials.gov, TrialNet, academic centers
Recruiting trials can be filtered by age, geography, disease stage, intervention class, and travel burden without storing sensitive profiles by default.
YouTube, creator feeds, podcasts, community submissions
Creator posts can surface practical lived experience and early buzz, but must be separated from clinical claims and sponsor influence.
A live PubMed query for T1D cure-watch, beta-cell, immunotherapy, stem-cell, islet, and technology terms. Preprints stay labeled separately until peer review.
ClinicalTrials.gov recruiting studies for Type 1 diabetes, used for NCT tracking, eligibility watch, intervention class, and location filters.
TrialNet is the first stop for family risk screening, prevention studies, and early-stage disease-modifying research pathways.
Breakthrough T1D organizes current clinical trial education, disease-modifying therapy trials, cell therapy trials, and virtual trial options.
The highest-priority safety lane for CGM, pump, sensor, infusion, app, blood-glucose monitor, and connected-device notices.
The clinical guideline anchor for diabetes care, technology, screening, hypoglycemia, school planning, and clinician-facing recommendations.
A stable government-backed patient education reference for Type 1 diabetes basics, symptoms, diagnosis, insulin, and family education.
A patient-community lens for daily-life topics, advocacy, family experience, practical gear, and stories that need evidence overlay.